Pfizer Inc. is reorganizing its commercial operations into three business segments led by top executives, grouping consumer health products with vaccines and oncology products, a move broadly in line with plans the firm outlined in discussions over the past two years with analysts.
Beginning Jan. 1, 2014, Pfizer will operate with an Innovative Products Group, responsible for drugs in therapeutic areas that are...
Welcome to HBW Insight
Create an account to read this article
Already a subscriber?